Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.9K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.9K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.9K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.6K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Polyphenolic Components and Phytochemicals Deployed as Nutraceuticals and Pharmafoods.

Food science & nutrition·2026
Same author

Assessing collagenase-a and type-II mediated degradation of human type-I collagen by photoacoustic spectroscopy toward clinical translation in cancer progression.

Scientific reports·2026
Same author

Liquid time constant based neuromorphic active inference for resilient control and health aware battery management in hybrid AC/DC microgrids.

Scientific reports·2026
Same author

Formation of Bimetallic Nanoparticles via Exsolution Using a Reducible Metal Oxide Capping Layer.

ACS nano·2026
Same author

A Non-randomized Clinical Trial on the Effectiveness and Complications of Two Different Streptokinase Dosages in Elderly Patients With ST-Elevation Myocardial Infarction (STEMI).

Cureus·2026
Same author

Transfusion requirements in acute coronary syndrome patients undergoing thrombolysis or anticoagulation: A retrospective cohort study.

Bioinformation·2026

Related Experiment Video

Updated: Mar 14, 2026

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
12:37

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

Published on: February 9, 2016

14.0K

Role of β-Blockers Across the Cardiovascular Continuum: A Real-World Perception Survey (ROBUST).

J S Hiremath1, Arup Dasbiswas2, Jps Sawhney3

  • 1Interventional Cardiologist, Ruby Hall Clinic, Pune, India.

The Journal of the Association of Physicians of India
|March 12, 2026
PubMed
Summary

Indian healthcare professionals commonly prescribe beta-blockers for hypertension and cardiovascular diseases. Metoprolol is the preferred beta-blocker across various conditions, indicating strong clinical acceptance in India.

More Related Videos

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

4.2K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.1K

Related Experiment Videos

Last Updated: Mar 14, 2026

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine
12:37

Surgical Placement of Catheters for Long-term Cardiovascular Exercise Testing in Swine

Published on: February 9, 2016

14.0K
Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis
08:05

Cardiac Response to β-Adrenergic Stimulation Determined by Pressure-Volume Loop Analysis

Published on: May 19, 2021

4.2K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.1K

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • High burden of hypertension (HTN) and cardiovascular (CV) diseases in India necessitates understanding healthcare professionals' (HCPs) perceptions of beta (β)-blockers.
  • Current prescribing patterns and perceived barriers for β-blockers in India are not well-documented.

Purpose of the Study:

  • To assess the utilization patterns, prescribing preferences, and perceived barriers of β-blockers among Indian HCPs.
  • To understand the real-world prescribing practices for β-blockers in managing hypertension and cardiovascular diseases in India.

Main Methods:

  • A cross-sectional survey was conducted among 1,000 Indian HCPs (physicians, cardiologists, diabetes/metabolism specialists).
  • A 26-item structured questionnaire assessed β-blocker utilization, preferences, and barriers.
  • Data from 855 HCPs were analyzed.

Main Results:

  • β-blockers were prescribed to 25-50% of hypertension patients by 57.2% of HCPs.
  • Common indications included heart failure (44.6%), post-myocardial infarction (25%), and chronic coronary syndrome (36.1%).
  • Metoprolol was the preferred agent in 75% of HTN, post-MI, CCS, and AF cases, and 66.2% for HF.

Conclusions:

  • This survey reveals current prescribing patterns and perceptions of β-blockers in India.
  • Metoprolol is the most preferred β-blocker for multiple cardiovascular indications in India.
  • Findings reflect metoprolol's strong clinical acceptance and perceived efficacy among Indian HCPs.